We had the great pleasure of meeting with Andrew Blumenfeld (Director, Headache, The Neurology Center of Southern California, Carlsbad, CA, USA) to discuss the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine.
The abstract ‘Combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
- What is the rationale for the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine? (0:17)
- Could you tell us a little about the aims, method and findings of the longitudinal chart review you conducted? (1:56)
- What did we learn in terms of safety and tolerability? (9:18)
Disclosures: Andrew Blumenfeld is on the advisory board for Allergan, Abbvie, Aeon, Alder, Amgen, Axsome, Biohaven, Impel, Lundbeck, Lilly, Novartis, Revance, Teva, Theranica, and Zosano Pharma; a speaker for Allergan, Abbvie, Amgen, Biohaven, Lundbeck, Lilly, and Teva; a consultant for Allergan, Abbvie, Alder, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva, and Theranica; receives grant support from Allergan and Amgen; and is a contributing author for Allergan, Abbvie, Amgen, Novartis, Teva, Lilly, and Biohaven.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021
Share this Video
Related Videos In Headache Disorders
Serena Orr, AHS 2021: Stress and Peak Pain Severity in Chronic Migraine
We had the great pleasure of meeting with Dr. Serena Orr (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) to discuss the relationship between peak pain severity in chronic migraine, and its relationship to stress. The abstract ‘The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study […]
Jessica Ailani, EAN 2021: Phase 3b CONQUER Trial Results
It was a great pleasure to meet with Jessica Ailani (MedStar Georgetown, Georgetown University Hospital, Pasquerilla Healthcare Center, Washington, WA, USA) to discuss the impact of galcanezumab on migraine care in the phase 3b CONQUER trial. The abstract entitled: ‘Total pain burden in patients with treatment-resistant migraine: effects of galcanezumab in the CONQUER Phase 3b […]
Michael Marmura, AHS 2021: Intranasal Ketamine for the Treatment of Refractory Headache
touchNEUROLOGY met with Michael Marmura (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss his study investigating intranasal ketamine for the treatment of refractory headache. The abstract ‘Intranasal Ketamine for Refractory Headache’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021. Questions: What is the rationale […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!